Your browser doesn't support javascript.
loading
Considerations in the developability of peptides for oral administration when formulated together with transient permeation enhancers.
Berg, Staffan; Edlund, Helena; R F Goundry, William; A S Bergström, Christel; Davies, Nigel M.
Affiliation
  • Berg S; Advanced Drug Delivery, Pharmaceutical Science, R&D, AstraZeneca, Gothenburg, Sweden; The Swedish Drug Delivery Center, Department of Pharmacy, Uppsala University, Biomedicinskt Centrum, Uppsala, Sweden.
  • Edlund H; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • R F Goundry W; Early Chemical Development, Pharmaceutical Science, R&D, AstraZeneca, Macclesfield, United Kingdom.
  • A S Bergström C; The Swedish Drug Delivery Center, Department of Pharmacy, Uppsala University, Biomedicinskt Centrum, Uppsala, Sweden.
  • Davies NM; Advanced Drug Delivery, Pharmaceutical Science, R&D, AstraZeneca, Gothenburg, Sweden. Electronic address: nigel.davies@astrazeneca.com.
Int J Pharm ; 628: 122238, 2022 Nov 25.
Article in En | MEDLINE | ID: mdl-36174850
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptides / Drug Delivery Systems Language: En Journal: Int J Pharm Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptides / Drug Delivery Systems Language: En Journal: Int J Pharm Year: 2022 Document type: Article